What GLP-1 users should know about the potential risk of a rare type of vision loss
Over 4,000 complaints have been filed against GLP-1 manufacturers, including Eli Lilly and Novo Nordisk, alleging that drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound caused users to lose their vision. Patients report sudden onset blindness, with some describing the experience as lights out. While these cases are described as rare, the volume of legal action suggests a growing concern over the potential link between these weight-loss and diabetes medications and permanent sight impairment. Medical professionals are currently evaluating the risk associated with these specific drug classes.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ More than 4,000 complaints have been filed against GLP-1 manufacturers alleging vision loss caused by Ozempic, Wegovy, Mounjaro, and Zepbound.
- ✓ Patients have filed lawsuits against GLP-1 drugmakers regarding the risk of sudden vision loss.
What changed
Lawsuits have been filed by hundreds of patients following over 4,000 complaints linking GLP-1 drugs to sudden blindness.
Live updates
-
Patients Sue GLP-1 Manufacturers Over Rare Vision Loss Risks
Over 4,000 complaints have been filed against GLP-1 manufacturers, including Eli Lilly and Novo Nordisk, alleging that drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound caused users to lose their vision. Patients report sudden onset blindness, with some describing the experience as lights out. While these cases are described as rare, the volume of legal action suggests a growing concern over the potential link between these weight-loss and diabetes medications and permanent sight impairment. Medical professionals are currently evaluating the risk associated with these specific drug classes.
Why it matters
GLP-1 receptor agonists are widely used for managing type 2 diabetes and obesity. The emergence of sudden vision loss as a potential side effect introduces a serious safety concern for millions of users. These lawsuits seek to determine if manufacturers failed to warn patients about these rare ocular risks.
What is confirmed
- More than 4,000 complaints have been filed against GLP-1 manufacturers alleging vision loss caused by Ozempic, Wegovy, Mounjaro, and Zepbound.
- Patients have filed lawsuits against GLP-1 drugmakers regarding the risk of sudden vision loss.
Still unconfirmed
- A woman lost vision in her right eye after using a GLP-1 drug for weight loss.
What to watch next
- Court rulings on the liability of Eli Lilly and Novo Nordisk
- Clinical studies confirming a causal link between GLP-1s and specific types of vision loss
- Updated FDA warning labels regarding ocular side effects for GLP-1 medications
confidence 90%Sources used for this update (9)
- Boston 25 News — ‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
- USA Today — Are GLP-1s causing blindness? What we know about rare cases
- NewsNation — Patients sue GLP-1 makers over sudden loss of vision
- ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
- WSJ — Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss
- The Boston Globe — Could GLP-1s be linked to a rare type of vision loss? Here’s what to know.
- www.nbcdfw.com — Woman details losing vision in 1 eye after taking GLP-1 as hundreds of patients sue drug companies
- www.mycentraloregon.com — Eating more ultra-processed foods linked to worse health, study finds
- in.mashable.com — Does Ozempic & Mounjaro Cause Blindness? What We Know About Eli Lilly and Novo Nordisk's Controversy
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community